| Prev Close | 12.26 |
| Open | 12.39 |
| Day Low/High | 12.00 / 12.46 |
| 52 Wk Low/High | 4.20 / 10.54 |
| Volume | 123.14K |
| Avg Volume | 342.60K |
| Exchange | NASDAQ |
| Shares Outstanding | 47.09M |
| Market Cap | 559.86M |
| EPS | -1.10 |
| P/E Ratio | N/A |
| Div & Yield | N.A. (N.A) |
Latest News
GenMark Diagnostics Commences Public Offering Of Common Stock
GenMark Diagnostics, Inc. (NASDAQ: GNMK), a leading provider of automated, multiplex molecular diagnostic testing systems, announced today that it has commenced an underwritten public offering of $65,000,000 of shares of...
GenMark Receives FDA 510(k) Market Clearance For Its EPlex® Instrument And Respiratory Pathogen Panel
GenMark Diagnostics, Inc. (Nasdaq:GNMK), a leading provider of automated, multiplex molecular diagnostic testing systems, today announced that it has received 510(k) market clearance from the U.
GenMark Diagnostics To Present At The 2017 William Blair Growth Stock Conference
GenMark Diagnostics, Inc. (NASDAQ: GNMK), a leading provider of automated, multiplex molecular diagnostic testing systems, will present at the 2017 William Blair Growth Stock Conference in Chicago on Tuesday, June 13, 2017.
Interesting GNMK Call Options For May 19th
Investors in GenMark Diagnostics, Inc. saw new options begin trading this week, for the May 19th expiration.
GenMark Diagnostics To Present At The Bank Of America Merrill Lynch 2017 Health Care Conference
GenMark Diagnostics, Inc. (NASDAQ: GNMK), a leading provider of automated, multiplex molecular diagnostic testing systems, will present at the Bank of America Merrill Lynch 2017 Health Care Conference in Las Vegas, Nevada,...
GenMark Diagnostics Reports First Quarter 2017 Results
GenMark Diagnostics, Inc. (Nasdaq:GNMK), a leading provider of automated, multiplex molecular diagnostic testing systems, today announced financial results for the first quarter ended March 31, 2017.
GenMark Achieves CE Mark For Its EPlex® Blood Culture Identification Fungal Pathogen Panel
GenMark Diagnostics, Inc. (Nasdaq:GNMK), a leading provider of automated, multiplex molecular diagnostic testing systems, today announced it has achieved CE Mark under the European In-Vitro Diagnostic Devices...
GenMark Diagnostics Schedules First Quarter 2017 Financial Results Conference Call For May 2, 2017
GenMark Diagnostics, Inc. (NASDAQ:GNMK) today announced that it plans to release its first quarter earnings results after market close on Tuesday, May 2, 2017.
GenMark Diagnostics To Present At 16th Annual Needham Healthcare Conference
GenMark Diagnostics, Inc. (NASDAQ: GNMK), a leading provider of automated, multiplex molecular diagnostic testing systems, will present at the 16 th Annual Needham Healthcare Conference to be held at the Westin Grand...
GenMark Diagnostics To Present At Cowen And Company's 37th Annual Health Care Conference
GenMark Diagnostics, Inc. (NASDAQ: GNMK), a leading provider of automated, multiplex molecular diagnostic testing systems, will present at Cowen and Company's 37 th Annual Health Care Conference to be held at the Marriott...
GenMark Diagnostics Reports Fourth Quarter And Full Year 2016 Results
GenMark Diagnostics, Inc. (Nasdaq:GNMK), a leading provider of automated, multiplex molecular diagnostic testing systems, today announced financial results for the fourth quarter and year ended December 31, 2016.
GenMark Diagnostics Schedules Fourth Quarter 2016 Financial Results Conference Call For February 28, 2017
GenMark Diagnostics, Inc. (NASDAQ:GNMK) today announced that it plans to release its fourth quarter earnings results after market close on Tuesday, February 28, 2017.
7 Stocks Making Big Moves With Unusual Volume
Here's a technical look at how to trade stocks rising with unusual volume flow.
Insiders Seeing Green With GNMK At New 52-Week High
In trading on Tuesday, shares of GenMark Diagnostics, Inc. touched a new 52-week high of $13.42/share.
This Small-Cap Rotation Is Unconvincing
Traders, pressed to find some action, are chasing certain things to a ridiculous extent.
GenMark Announces Preliminary Q4 2016 Financial Results
GenMark Diagnostics, Inc. (Nasdaq:GNMK), a leading provider of automated, multiplex molecular diagnostic testing systems, today reported preliminary fourth quarter 2016 revenue of $14.
GenMark Diagnostics To Present At The 2017 J.P. Morgan Healthcare Conference
GenMark Diagnostics, Inc. (NASDAQ: GNMK), a leading provider of automated, multiplex molecular diagnostic testing systems, will present at the 2017 J.
Commit To Purchase GenMark Diagnostics At $10, Earn 17.6% Annualized Using Options
Investors eyeing a purchase of GenMark Diagnostics, Inc. shares, but tentative about paying the going market price of $12.23/share, might benefit from considering selling puts among the alternative strategies at their disposal.
GenMark Diagnostics Submits 510(k) Applications To The FDA For EPlex® Sample-to-Answer Instrument And Respiratory Pathogen Panel
GenMark Diagnostics, Inc. (Nasdaq:GNMK), a leading provider of automated, multiplex molecular diagnostic testing systems, today announced that it has submitted 510(k) applications to the FDA for its ePlex sample-to-answer...
GenMark Diagnostics Reports Q3 Financial Results
GenMark Diagnostics, Inc. (Nasdaq:GNMK), a leading provider of automated, multiplex molecular diagnostic testing systems, today announced financial results for the third quarter ended September 30, 2016.
GenMark Diagnostics To Present At The Canaccord Genuity Medical Technologies & Diagnostics Forum
GenMark Diagnostics, Inc. (NASDAQ: GNMK), a leading provider of automated, multiplex molecular diagnostic testing systems, announced today that Hany Massarany, President and Chief Executive Officer, will present at the...
GenMark Diagnostics Schedules Third Quarter 2016 Financial Results Conference Call For November 3, 2016
GenMark Diagnostics, Inc. (NASDAQ:GNMK) today announced that it plans to release its third quarter earnings results after market close on Thursday, November 3, 2016.
GenMark Diagnostics (GNMK) Stock Soars, Cowen Upgrades
Cowen lifted GenMark Diagnostics (GNMK) stock rating to 'outperform,' citing positive reception of its ePlex device.
GenMark Diagnostics Reports Q2 Financial Results
GenMark Diagnostics, Inc. (Nasdaq:GNMK), a leading provider of automated, multiplex molecular diagnostic testing systems, today announced financial results for the second quarter ended June 30, 2016.
GenMark Diagnostics To Present At The 36th Annual Canaccord Genuity Growth Conference
GenMark Diagnostics, Inc. (NASDAQ: GNMK), a leading provider of automated, multiplex molecular diagnostic testing systems, announced today that Hany Massarany, President and Chief Executive Officer, will present at the 36th...
GenMark Diagnostics Schedules Second Quarter 2016 Financial Results Conference Call For July 28, 2016
GenMark Diagnostics, Inc. (NASDAQ:GNMK) today announced that it plans to release its second quarter earnings results after market close on Thursday, July 28, 2016.
GenMark Achieves CE Mark For Its EPlex® Sample-to-Answer System
GenMark Diagnostics, Inc. (Nasdaq:GNMK), a leading provider of automated, multiplex molecular diagnostic testing systems, today announced it has achieved CE Mark under the European In-Vitro Diagnostic Devices...
Insider Trading Alert - GNMK, CLRO And ADSK Traded By Insiders
Stocks with insider trader activity include GNMK, CLRO and ADSK
